Research programme: Delta 5 desaturase inhibitors - DS Biopharma
Latest Information Update: 28 Nov 2025
At a glance
- Originator North Dakota State University
- Developer DS Biopharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Delta 5 fatty acid desaturase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Nov 2025 No recent reports of development identified for preclinical development in Solid-tumours(Combination therapy) in Ireland
- 21 Oct 2022 Research programme: Delta 5 desaturase inhibitors - DS Biopharma is available for licensing as of 21 Oct 2022. https://www.dsbiopharma.com/partnering/
- 14 Oct 2021 DS Biopharma inlicenses delta 5 desaturase (D5D) inhibitors from North Dakota State University